MGTX
MeiraGTx HoldingsยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
MGTX Profile
Meiragtx Holdings Plc
A US-based clinical-stage gene therapy company developing treatments for rare genetic disorders and ophthalmic diseases
Biological Technology
05/01/2018
06/08/2018
NASDAQ Stock Exchange
375
12-31
Common stock
655 Third Avenue
Suite 1115
New York
NY 10017
--
MeiraGTx Holdings plc was incorporated under the laws of the Cayman Islands on May 1, 2018. The company is a vertically integrated clinical-stage gene therapy company with six clinical development programs and an extensive pipeline of preclinical and research programs. The company has core capabilities in viral vector design and optimization and gene therapy manufacturing, as well as a potential transformational gene regulation platform technology that allows precise, dose-responsive control of gene expression through oral small molecules with a dynamic range of more than 5,000 times. The company's initial focus is on three distinct areas of unmet medical need: eye diseases, including hereditary retinal diseases, large degenerative eye diseases, neurodegenerative diseases and severe xerostomia.
